Safety and Tolerability of PF-06818883 in Healthy Subjects

NCT03020784 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-12-11

No results posted yet for this study

Summary

Safety, Tolerability and Pharmacokinetics of PF-06818883

Conditions

  • Healthy

Interventions

DRUG

Placebo

Placebo

DRUG

PF-06818883

Treatment

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-11-11
Primary Completion
2017-06-13
Completion
2017-06-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03020784 on ClinicalTrials.gov